(19)
(11) EP 1 791 852 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.04.2009 Bulletin 2009/14

(45) Mention of the grant of the patent:
31.12.2008 Bulletin 2009/01

(21) Application number: 05814242.3

(22) Date of filing: 23.09.2005
(51) International Patent Classification (IPC): 
C07H 7/04(2006.01)
(86) International application number:
PCT/US2005/034359
(87) International publication number:
WO 2006/034489 (30.03.2006 Gazette 2006/13)

(54)

C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION

C-ARYL-GLUCOSID-SGLT2-INHIBITOREN UND VERFAHREN ZU IHRER HERSTELLUNG

INHIBITEURS DE C-ARYL GLUCOSIDE SGLT2 ET PROCEDE POUR LEUR PRODUCTION

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
HR MK YU

(30) Priority: 23.09.2004 US 612599 P

(43) Date of publication of application:
06.06.2007 Bulletin 2007/23

(73) Proprietor: Bristol-Myers Squibb Company
Princeton NJ 08543-4000 (US)

(72) Inventors:
  • WASHBURN, William
    Titusville, NJ 08560 (US)
  • MENG, Wei
    Pennington, NJ 08534 (US)

(74) Representative: Hart-Davis, Jason et al
Cabinet Beau de Loménie, 158, rue de l'Université
75340 Paris Cedex 07
75340 Paris Cedex 07 (FR)


(56) References cited: : 
WO-A-03/099836
 WO-A-20/04063209
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).